INTRODUCTION
that esg ts >yki 3SA tumors show concomitant increase in Sd ( Figure 1D, J) , the DNA-binding 118 partner of Yki.
119
To test whether the fly equivalent of the 25 amino acid long TONDU domain of Vg 120 (CVVFTNYSGDTASQVDEHFSRALNY) can arrest neoplastic tumor progression similar to the 121 full length protein observed earlier (21), we examined somatic clones in wing imaginal discs that 122 lack the tumor suppressor lethal giant larvae (lgl) and that express an activated form of Yki 123 (UAS-yki S168A (36), referred to as lgl UAS-yki) and the TONDU peptide. Strikingly, marked 124 reduction in the growth of lgl UAS-yki UAS-vg TONDU tumors was observed as compared to their 125 lgl UAS-yki counterparts ( Figure S2A, B) .
126
Next, we examined the effect of TONDU expression on Yki-induced ISC tumors in the adult 127 midgut. Co-expression of TONDU and activated Yki (esg ts >yki 3SA UAS-vg TONDU ) revealed that 128 TONDU could inhibit Yki-driven ISC proliferation throughout the midgut, an effect that was 129 more striking in the anterior midgut ( Figure 1E ). Consistent with these observations, we also 130 noted a marked reduction in the number of GFP-marked ISCs ( Figure 1F 
141
Oral uptake of synthetic TONDU peptide inhibits Yki-driven ISC tumor 142 Next, we tested whether a synthetic TONDU peptide could inhibit Yki-driven ISC tumors akin to 143 endogenously expressed peptide. We fed adult flies with varying concentrations of TONDU 144 peptide linked to an HIV-TAT motif (RKKRRQRRR) and a nuclear localizing signal (NLS)
145
( Figure 2A ) to facilitate its cellular uptake (37) and nuclear localization, respectively. This TAT-
146
NLS-TONDU peptide is referred to as TONDU peptide in subsequent part of the text. Prior to its oral administration to adult flies we first confirmed cellular uptake of the fluorescent-labeled 148 TONDU peptide in S2R+ cells, as observed by its cytoplasmic and nuclear localization ( Figure   149 2B). Further, to test whether the TONDU peptide can inhibit Yki-Sd complex formation, we 150 used the Hippo-response-element (HRE)-luciferase reporter (23), which serves as a readout for
151
Yki-Sd transcriptional activity. Specifically, we co-transfected S2R+ cells with the reporter 152 along with Yki and Sd-expressing vectors, then treated the cells with 100 nM of TONDU 153 peptide, and observed a moderate but consistent decrease in luciferase activity ( Figure 2C ). Next,
154
to confirm binding of the synthetic TONDU peptide to Sd and subsequent inhibition of Yki-Sd 155 interaction, we carried out co-immunoprecipitation studies using FLAG-tagged TONDU peptide 156 in S2R + cells transfected with HA-Sd and GFP-Yki. Co-immunoprecipitation experiments 157 revealed that the Yki-Sd interaction is indeed significantly reduced upon incubating S2R+ cells 158 with TONDU for 24 hours ( Figure 2D ). Finally, when purified HA-Sd from S2R+ cells was 159 incubated with FLAG-tagged TONDU peptide, TONDU displayed binding with Sd, as revealed 160 by immunoblots using anti-Flag antibody ( Figure 2E ). Together, these results demonstrate that 161 TONDU can disrupt the Sd-Yki interaction by binding to Sd.
162
We next tested whether oral uptake of TONDU peptide could inhibit esg ts >yki 3SA tumors. To do 163 this, esg ts >yki 3SA flies were collected 24 hours post eclosion and fed for ten days on food 164 supplemented with TONDU peptide at a final concentration of 50, 100 or 200 µM. We noted a 165 progressive reduction in tumor mass ( Figure 2F -I), marked by a decrease in the number of GFP-166 marked ISCs ( Figure 2J ) with increasing concentration of TONDU peptide in the food. By 167 contrast, the tumor load was only moderately reduced when these flies were fed with a sequence-168 scrambled TONDU peptide ( Figure S3A ) at comparable concentrations (see Figure S3B -F); this 169 residual inhibition of ISC proliferation is presumably due to a partial retention of the secondary 170 structures necessary for TONDU activity (15) in the scrambled-TONDU peptide ( Figure S3G ).
171
Further, to confirm cellular uptake of TONDU peptide by the gut epithelia, we fed FLAG-tagged 172 TONDU peptide (at final concentration of 200 µM) to esg ts >yki 3SA flies, and detected its cellular 173 uptake in gut lysates followed by immunoblotting using the anti-FLAG antibody ( Figure S3H ).
174
In parallel, we also noted that feeding TONDU (at 200 µM) did not affect the numbers of ISCs in 175 control (esg ts >GFP) guts ( Figure S3I ). In addition, two cell lines derived from human tumors 176 with elevated YAP1 levels ( Figure S3J ), PC3 (prostate cancer cells) and COLO-320 (colorectal 177 cancer cells), displayed growth arrest upon uptake of TONDU peptide ( Figure 2K ), whereas a cell line with negligible levels of YAP1 ( Figure S3J ), LNCaP, did not ( Figure 2K ). Altogether, 179 these results suggest that TONDU is therapeutically relevant in a number of YAP-driven tumors 180 irrespective of their tissues of origin.
181
Yki-driven tumor proteome reveals enrichment in integrin pathway
182
We reasoned that proteins that are significantly perturbed in esg ts >yki 3SA tumors and restored to 183 normal levels following TONDU feeding may represent critical Yki-Sd targets that are critical to 184 ISC tumorigenesis, and, therefore, could be therapeutically relevant. Thus, we carried out a 185 proteome analysis using unlabeled LC-MS/MS of esg ts >yki 3SA tumors on day 1 and day 7 of 186 tumor induction, with or without TONDU peptide supplementation of the food. Altogether, we 187 identified 1219 proteins (including isoforms), corresponding to 2771 unique Uniprot IDs at an 188 FDR cutoff of q<0.05 ( Figure 3A , Table S1 ). We next compared the proteomes of esg ts >yki 3SA 189 tumors on day 7 versus day 1 of tumor induction, and prioritized those proteins which displayed 190 at least log 2 ±2 fold change (at a p value <0.05) for further analysis. Fold change was derived 191 from the abundance measure of peptides (for a given protein) in day 7 versus day 1 of 192 esg ts >yki 3SA tumors (See SI methods) and a list was generated of 127 differentially detected 193 proteins (corresponding to 144 unique Uniprot IDs, including isoforms) that matched to 55 194 unique genes ( Figure 3B and Table S2 ). For 45 of the 55 genes, the gene products showed a 195 >log 2 2 fold increase while 10 displayed <log 2 2 fold decrease in their protein levels in day 7 196 esg ts >yki 3SA tumors ( Figure 3B and Table S2 ).
197
To determine whether these enriched proteins in the ISC tumors have a significant biological 198 association we performed a protein-protein interaction (PPI)-network analysis using STRING 199 (38), which revealed significant (p<0.001) interaction among some of the enriched proteins 200 ( Figure 3C ). We note that the enriched gene-set include the secreted Wingless (Wg) transporter 201 Swim (39) and known members of the Hippo protein-protein interaction network (40), including 202 the junction proteins Coracle, Jar, and Misshapen (Table S3 ). Furthermore, comparison of the 203 esg ts >yki 3SA day 7 proteome with the recently published transcriptome (33) of esg ts >yki 3SA tumors 204 of comparable age revealed a close correlation between changes in proteins and their respective 205 transcript levels (r=0.548) ( Figure S4A ).
Next, to look for signaling pathways that were perturbed in Yki-driven ISC tumors, we 207 undertook a gene ontology (GO) classification of the genes enriched in esg ts >yki 3SA tumors. GO 208 classification revealed perturbations in several signaling pathways and protein classes ( Figure   209 3D, Table S4 ). In particular, we observed an increase in protein levels of key members of the 210 integrin signaling pathway, including Talin (2.39 log 2 fold), Talin-interacting adaptor proteins,
211
Vinculin (2.4 fold), and Paxillin (6.05 fold). Other members, such as αPS3 and integrin-linked 212 kinases, also displayed about a 2-fold change, albeit at p>0.05 (Table S5 ). Consistent with these 213 findings, a concomitant increase in the transcript levels of these proteins was observed in the 214 esg ts >yki 3SA transcriptome (33) ( Table S5 ). Further, many integrin pathway components,
215
including integrins αPS1, αPS2, αPS3 and βPS as well as integrin-binding ligands LamA and 216 LamB (33), which were not detected in our proteomic study, were also found to be 217 transcriptionally upregulated in the RNA-Seq data (Table S5 ). Proteome comparison between 218 day 7 and day 1 esg ts >yki 3SA tumors also displayed significant increase in protein levels of (Table S6 ). Interestingly,
232
several key members of the integrin pathway, including mew, which codes for integrin αPS1, the food, suggesting that mew transcription is most likely regulated by Sd in the ISCs.
244
We next compared the gut proteomes of esg ts >yki 3SA flies fed on TONDU peptide-supplemented 245 food and those displaying co-expression of the TONDU peptide (esg ts >yki 3SA UAS-vg TONDU ), to 246 esg ts >yki 3SA flies of comparable age (day 7) raised on normal food ( Figure 2G , H). In particular,
247
we examined the status of proteins in TONDU-peptide-treated proteome that were ±>log 2 2 fold 248 perturbed in untreated tumors ( Figure 3B and Table S2 ). We observed an overall decrease in the 249 protein levels of perturbed genes in peptide-fed tumors ( Figure 3G ), which coincided with a 250 decrease in protein levels of genes involved in generic cellular processes such as RNA (Table S7) . 
